New cocktail aims to shrink stomach tumors before surgery
NCT ID NCT07165847
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether adding radiotherapy and two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy can improve outcomes for people with resectable stomach or gastroesophageal junction cancer. About 40 participants will be randomly assigned to receive either the new combination or standard treatment before surgery. The main goal is to see how many patients have no cancer cells left in the removed tissue (pathological complete response).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iparomlimab and tuvonralimab (immunotherapy drugs), oxaliplatin and tegafur (chemotherapy), plus radiotherapy
What this could lead to
If successful, this combination could improve the chance of eliminating all visible cancer before surgery, potentially leading to better long-term outcomes for patients with gastric cancer.
What could go wrong
This is an early phase 2 trial with only 40 participants, so results may not apply to everyone. Adding immunotherapy and radiation to chemotherapy also increases the risk of side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER (GC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Army Medical Center
RECRUITINGChongqing, Other (Non U.s.), 400000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••